SLS — Sellas Life Sciences Share Price
0.000.00%
Last trade - 00:00- $164.51m
- $150.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 17.38 | ||
| Price to Tang. Book | 21.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -317.61% | ||
| Return on Equity | -4147.88% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.9 | 7.6 | 1 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Directors
- Jane Wasman NEC (64)
- Angelos Stergiou PRE (45)
- Barbara Wood EVP (59)
- Dragan Cicic SVP (57)
- John Burns CAO (36)
- David Scheinberg DRC (65)
- Robert Van Nostrand IND (64)
- John Varian IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 3rd, 2006
- Public Since
- March 12th, 2008
- No. of Shareholders
- 13
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 94,548,425
- Address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, 10036
- Web
- https://www.sellaslifesciences.com/
- Phone
- +1 6462005278
- Auditors
- MOSS ADAMS LLP
Upcoming Events for SLS
Sellas Life Sciences Group Inc Annual Shareholders Meeting
Sellas Life Sciences Group Inc Annual Shareholders Meeting
Q2 2025 Sellas Life Sciences Group Inc Earnings Release
Similar to SLS
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Sellas Life Sciences share price?
As of Today at 23:09 UTC, shares in Sellas Life Sciences are trading at $1.74. This share price information is delayed by 15 minutes.
How has the Sellas Life Sciences share price performed this year?
Shares in Sellas Life Sciences last closed at $1.74 and the price had moved by +28.89% over the past 365 days. In terms of relative price strength the Sellas Life Sciences share price has outperformed the S&P500 Index by +16.22% over the past year.
What are the analyst and broker recommendations for Sellas Life Sciences?
The overall consensus recommendation for Sellas Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sellas Life Sciences dividend yield?
Sellas Life Sciences does not currently pay a dividend.
Does Sellas Life Sciences pay a dividend?
Sellas Life Sciences does not currently pay a dividend.
When does Sellas Life Sciences next pay dividends?
Sellas Life Sciences does not currently pay a dividend.
How do I buy Sellas Life Sciences shares?
To buy shares in Sellas Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sellas Life Sciences?
As of the previous close price of $1.74, shares in Sellas Life Sciences had a market capitalisation of $164.51m.
Where are Sellas Life Sciences shares listed?
Here are the trading details for Sellas Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SLS
What kind of share is Sellas Life Sciences?
Based on an overall assessment of its quality, value and momentum Sellas Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sellas Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in Sellas Life Sciences is $5.83. That is 235.06% above the last closing price of $1.74.
Analysts covering Sellas Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.43 for the next financial year.
Find out moreWhat is the trend in the Sellas Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sellas Life Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +46.89%.
As of the last closing price of $1.74, shares in Sellas Life Sciences were trading +45.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sellas Life Sciences PE Ratio?
The Sellas Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sellas Life Sciences?
Sellas Life Sciences' management team is headed by:
- Jane Wasman - NEC
- Angelos Stergiou - PRE
- Barbara Wood - EVP
- Dragan Cicic - SVP
- John Burns - CAO
- David Scheinberg - DRC
- Robert Van Nostrand - IND
- John Varian - IND